CareDx Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,542.00
1,033.00
13,707.00
39,756.00
55,560.00
46,781
Depreciation, Depletion & Amortization
663.00
512.00
796.00
2,920.00
3,759.00
4,215
Other Funds
-
3,733.00
-
-
9,375.00
39,430
Funds from Operations
1,922.00
1,064.00
11,581.00
19,334.00
15,263.00
4,743
Changes in Working Capital
1,376.00
2,286.00
1,829.00
2,811.00
956.00
736
Net Operating Cash Flow
546.00
3,350.00
9,752.00
16,523.00
14,307.00
4,007
Capital Expenditures
98.00
733.00
1,199.00
549.00
186.00
Purchase/Sale of Investments
-
-
-
-
59.00
Net Investing Cash Flow
98.00
1,333.00
1,199.00
21,117.00
6,164.00
Issuance/Reduction of Debt, Net
58.00
454.00
4,159.00
3,944.00
9,706.00
Net Financing Cash Flow
58.00
35,986.00
4,408.00
24,927.00
20,004.00
Net Change in Cash
702.00
31,303.00
6,543.00
12,630.00
363.00
Free Cash Flow
644.00
4,083.00
10,951.00
17,072.00
14,493.00
Deferred Taxes & Investment Tax Credit
-
-
-
1,340.00
2,088.00
1,607
Net Assets from Acquisitions
-
600.00
-
20,568.00
5,919.00
Change in Capital Stock
-
39,265.00
249.00
28,871.00
19,673.00
Exchange Rate Effect
-
-
-
83.00
104.00

About CareDx

View Profile
Address
3260 Bayshore Boulevard
Brisbane California 94005
United States
Employees -
Website http://www.caredxinc.com
Updated 07/08/2019
CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test.